ncbi.nlm.nih.gov · May 1, 2026 10:00 AM UTC

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project

Summary

Our analysis showed worse survival outcomes in pretreated mUC with ECOG-PS 2 receiving EV monotherapy; however, given the retrospective design and baseline imba...

Original reporting

Open original source

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project

Summary

Original reporting

Related coverage

Pentagon AI deals bring NVIDIA, Microsoft tools to classified systems

A Husband and Wife Escaped From a Locked Memory-Care Unit. He Solved the Door Code Just by Listening.

Prevention Efforts Increasingly See Suicide Through a Broader Lens

Golf has never seen anything more embarrassing than this. And now it’s dead.

There’s a specific version of loneliness that arrives only after retirement — not the absence of colleagues, but the discovery that nearly every meaningful adult interaction was being subsidized by th

Worried about how online firms use data they get from you? — Harvard Gazette